8-K: Amwell Reports Strong Q2 2026 Results, Raises 2026 Outlook

Amwell announced its second quarter 2026 financial results, showcasing total revenue at the top end of guidance, improved gross margin, and a narrowed net loss, while also raising its full-year revenue and Adjusted EBITDA outlook.

Summary

• Amwell reported total revenue of $52.0 million for the second quarter of 2026, meeting the high end of its guidance.
• Subscription revenue reached $25.7 million, and Amwell Medical Group (AMG) visit revenue was $24.4 million.
• Gross margin stood at 53%.
• The net loss for the quarter was ($9.6) million, an improvement from ($10.3) million in Q1 2026.
• Adjusted EBITDA improved to ($1.2) million from ($3.1) million in Q1 2026.
• Total visits on the platform were 0.8 million.
• The company is projecting positive cash flows from operations for Q4 2026.
• Amwell raised its full-year 2026 revenue outlook to $200 million $205 million and increased its Adjusted EBITDA guidance to ($9) million ($7) million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with significant improvements in financial metrics and a strengthened outlook, despite continued net losses.

Positives

• Total revenue met the top end of guidance at $52.0 million.
• Subscription revenue is approaching half of total revenue.
• Gross margin improved to 53%.
• Net loss narrowed to ($9.6) million from ($10.3) million in the prior quarter.
• Adjusted EBITDA significantly improved to ($1.2) million from ($3.1) million in the prior quarter.
• Full-year 2026 revenue outlook was raised to $200 million $205 million.
• Full-year 2026 Adjusted EBITDA guidance was improved to ($9) million ($7) million.
• Positive cash flows from operations are projected for Q4 2026.

Negatives

• The company reported a net loss of ($9.6) million for the second quarter of 2026.
• Adjusted EBITDA remains negative at ($1.2) million for the quarter.
• The company is still projecting a full-year Adjusted EBITDA loss between ($9) million and ($7) million.

Risks

• Weak growth and increased volatility in the telehealth market.
• The ability to adapt to rapid technological changes.
• Increased competition from existing and potential new participants in the healthcare industry.
• Changes in healthcare laws, regulations, or trends and the ability to operate in the heavily regulated healthcare industry.
• The ability to comply with federal and state privacy regulations.
• Significant liability that could result from a cybersecurity breach.
• The ability to commence and complete strategic transformation initiatives and their impact.
• The election by the Defense Health Agency to deploy our solution across their entire enterprise and the continuation of this relationship beyond Q3 2026 with comparable financial terms.

Future Outlook

Amwell is raising its full-year 2026 revenue outlook to a range of $200 million to $205 million and improving its Adjusted EBITDA guidance to a range of ($9) million to ($7) million. The company also expects Q3 2026 revenue between $46 million and $48 million, with Adjusted EBITDA between ($5) million and ($3) million. A key objective is to achieve positive cash flow from operations in the fourth quarter of 2026.

Management Comments

• "The DHAs intent to make Amwell a prime contractor is a powerful endorsement of our platform and our people," said Dr. Ido Schoenberg, Chairman and CEO of Amwell.
• "With subscription revenue now approaching half our total revenue, independently validated behavioral clinical outcomes, no debt, and positive cash flows from operations projected for the fourth quarter this year, we have never been better positioned to lead the era of AI-powered care."

Industry Context

StockSavvy.ai notes that Amwell's performance, particularly the growth in subscription revenue and the focus on AI-powered care, aligns with broader industry trends towards platform-based, recurring revenue models in digital health. The company's ability to secure a prime contractor role with the DHA is a significant validation in a competitive landscape.

Comparison to Industry Standards

• The reported gross margin of 53% is a key indicator of operational efficiency within the telehealth and digital health platform sector.
• The improvement in Adjusted EBITDA, moving from ($3.1) million to ($1.2) million quarter-over-quarter, demonstrates progress towards profitability, a critical benchmark for many SaaS-based healthcare companies.
• The projected positive cash flow from operations in Q4 2026 is a significant milestone, as many companies in this sector are still focused on growth at the expense of immediate cash flow generation.

Related Party Transactions

• Accounts receivable included $30 and $955 from related parties as of June 30, 2026 and December 31, 2025, respectively.
• Deferred revenue included $20 and $113 from related parties as of June 30, 2026 and December 31, 2025, respectively.
• Revenue included ($34, $833, $614 and $1,265) from related parties for the three months ended June 30, 2026 and 2025, and the six months ended June 30, 2026 and 2025, respectively.

Stakeholder Impact

• Shareholders: The raised outlook and improved financial metrics are positive indicators, potentially leading to increased investor confidence.
• Customers: Continued platform development and potential expansion with the DHA could lead to enhanced services and broader access to care.
• Employees: The focus on strategic transformation and AI-powered care may lead to evolving roles and opportunities within the company.

Next Steps

• Host conference call to discuss financial results.
• Continue to transition clients to the current platform.
• Focus on renewing and upselling to the client base.
• Monitor the Defense Health Agency's decision to deploy the solution across their entire enterprise.
• Achieve positive cash flow from operations in Q4 2026.

Key Dates

Recommendation

The company is showing positive operational improvements and has raised its guidance, indicating a strengthening business trajectory. However, it continues to operate at a net loss and with negative Adjusted EBITDA, suggesting that while the direction is positive, it has not yet reached sustainable profitability. Therefore, a 'hold' recommendation reflects cautious optimism, awaiting further evidence of sustained profitability and cash flow generation.

Keywords

telehealth, healthcare platform, SaaS, financial results, revenue, Adjusted EBITDA, visits, AI-powered care